Sanofi and CD&R entered into exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella.

The growth rate of the consumer healthcare business could accelerate now that an activist investor is involved.

Jefferies analyst Keith Devas initiated coverage with a Buy rating on Kenvue, Inc. (KVUE – Research Report) today and set a price target ...

On Tuesday, Kenvue Inc (KVUE) stock saw a modest uptick, ending the day at $22.93 which represents a slight increase of $0.01 or 0.04% from the prior close of $22.92. The stock opened at $22.55 and ...

(Reuters) -Hedge fund Starboard Value has taken a stake in Kenvue, the consumer products company that makes Band-Aid, ...

Starboard Chief Executive Jeff Smith said that Kenvue, the Tylenol-maker spun out from Johnson & Johnson, should drill down on fixing its underperforming skin health and beauty segment, which he ...

Financial writer analyzes activist hedge fund CEO's call for Kenvue to revamp skincare, health, and beauty segments for ...

An exclusive Q&A with David Lickstein, Global Head of Packaging Innovation, Sustainability, and Experience, at Kenvue ...

Hedge fund Starboard Value called consumer products company Kenvue a bargain and said its skin health and beauty segment's ...

Starboard Value contends that Kenvue, with strong consumer health brands like Tylenol and Listerine, is underperforming its ...

Kenvue, Inc. (KVUE – Research Report), the Technology sector company, was revisited by a Wall Street analyst yesterday. Analyst Anna ...

By Svea Herbst-Bayliss (Reuters) -Hedge fund Starboard Value called consumer products company Kenvue a bargain and said its ...